BLOG
    FAQ
    X
    Visit blog page
    OZEMPIC® 1mg (Italian)  distributors
    OZEMPIC® 1mg (Italian)  distributors
    OZEMPIC® 1mg (Italian)  distributors

    Buy OZEMPIC® 1mg (Italian) Online

    (0)

    0

    brand:

    OZEMPIC®

    manufacturer:

    Novo Nordisk

    active substances:

    SEMAGLUTIDE

    strength:

    1mg

    pack size:

    1 pen, 4 disposable NovoFine® Plus needles (4 Doses)

    INFORMATION

    Product Description

    OZEMPIC® 1mg (Italian) Indications for Use

    OZEMPIC® 1mg (Italian) (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for:

    • Type 2 Diabetes Mellitus: Used as an adjunct to diet and exercise to improve glycemic control in adults.
    • Cardiovascular Risk Reduction: Reduces the risk of major adverse cardiovascular events (e.g., cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.

    Limitations:

    • Not recommended for patients with type 1 diabetes mellitus.
    • Not studied in patients with a history of pancreatitis​.

    OZEMPIC® 1mg (Italian) Dosage Information

    OZEMPIC® 1mg (Italian) is administered via a subcutaneous injection, typically once weekly. The injection can be taken at any time of day, with or without food. The initial dose is gradually increased to achieve better glycemic control:

    • Starting dose: 0.25 mg once weekly for the first 4 weeks (not effective for glycemic control).
    • Increase to 0.5 mg after 4 weeks. If additional glycemic control is needed, the dose can be increased to 1 mg once weekly after at least 4 weeks on the lower dose.
    • If further control is needed, the dose may be raised to 2 mg after 4 weeks on 1 mg​.

    OZEMPIC® 1mg (Italian) Side Effects and Precautions

    OZEMPIC® 1mg (Italian) has several common and serious side effects. It’s important to monitor patients closely for any adverse reactions.

    • Common Side Effects (occurring in more than 5% of patients):
      • Nausea (15.8-20.3% of patients)
      • Vomiting, diarrhea, abdominal pain, constipation​.
    • Serious Side Effects:
      • Thyroid C-cell tumors: In rodent studies, semaglutide caused dose-dependent thyroid tumors. It is unclear if this risk applies to humans. OZEMPIC® 1mg (Italian) is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)​.
      • Pancreatitis: Monitor for signs of pancreatitis (severe abdominal pain). Discontinue use if pancreatitis is confirmed​.
      • Hypoglycemia: Particularly when used with insulin or sulfonylurea​.
      • Acute kidney injury: Renal function should be monitored in patients with renal impairment who experience severe gastrointestinal side effects​.

    OZEMPIC® 1mg (Italian) Drug Interactions

    • Insulin Secretagogues (e.g., sulfonylureas): Co-administration increases the risk of hypoglycemia. Dose adjustments of insulin or insulin secretagogues may be needed to prevent this.
    • Oral Medications: OZEMPIC® 1mg (Italian) delays gastric emptying, which may affect the absorption of some oral medications​.

    OZEMPIC® 1mg (Italian) Contraindications

    • Personal or family history of MTC or MEN 2​.
    • Serious hypersensitivity reactions to semaglutide or any of the excipients​.

    Clinical Studies or Real-World Outcomes

    Several clinical trials support the efficacy of OZEMPIC® 1mg (Italian) in controlling blood sugar levels and reducing cardiovascular risks:

    • Monotherapy Trial:
      • Patients treated with OZEMPIC® 1mg (Italian) 1 mg saw an average HbA1c reduction of 1.6% after 30 weeks, compared to 0.1% for placebo. Approximately 70% of patients achieved HbA1c <7%​.
      • Weight loss averaged 4.7 kg for patients on 1 mg compared to 1.2 kg in the placebo group​.
    • Combination Therapy with Metformin:
      • In a 56-week trial, OZEMPIC® 1mg (Italian) combined with metformin resulted in a significant HbA1c reduction of 1.5% (for 1 mg dose) compared to sitagliptin​.
    • Cardiovascular Outcomes:
      • A 2-year cardiovascular trial showed that OZEMPIC® 1mg (Italian) significantly reduced the incidence of major adverse cardiovascular events compared to placebo​.

    OZEMPIC® 1mg (Italian) Use in Specific Populations

    • Pregnancy: OZEMPIC® 1mg (Italian) should be discontinued at least 2 months before a planned pregnancy due to the long washout period​.
    • Pediatrics: Safety and efficacy have not been established in patients under 18​.

    Renal and Hepatic Impairment: No dosage adjustment is necessary for patients with renal or hepatic impairment​.

    Related Products
    Shopping Bag0
    There are no products in the cart!